---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-000450"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:44:02.696843+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zai Lab partner Novocure's LUNAR study meets primary overall survival endpoint in stage 4 NSCLC

## Summary
- LUNAR study showed statistically significant and clinically meaningful improvement in overall survival vs standard therapies alone.
- TTFields + immune checkpoint inhibitors demonstrated significant OS benefit; positive trend with TTFields + docetaxel.
- Zai Lab has exclusive license to develop and commercialize TTFields in mainland China, Hong Kong, Macau, and Taiwan.
- Novocure plans to file PMA with FDA and CE Mark in EU in H2 2023; full results at future medical congress.

## SEC filing metadata
- accession: 0001628280-23-000450
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828023000450/0001628280-23-000450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828023000450/zlab-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-000450
- JSON: https://secwatch.observer/filing/0001628280-23-000450.json
- Plain text: https://secwatch.observer/filing/0001628280-23-000450.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.